Abstract
Vulvovaginal candidiasis today is one of the most pressing problems in the field of women’s health. However, the prevalence of Candida with formed drug resistance to fluconazole significantly complicates the treatment of this disease. Thus, the evaluation of the safety and efficacy of other antimycotic drugs becomes an important task in the fight against recurrent genital candidiasis. The article presents the data of international and domestic studies on the possibilities of using sertaconazole in the therapy of vulvovaginal candidiasis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.